DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation

Leukemia Research
Meilani SyampurnawatiYoshitake Hayashi

Abstract

Our previous observation of a higher incidence of FLT3-ITD in DR(-) M1/M2 AML than in DR(+) M1/M2 led to an investigation of NPM1 mutation in the same samples, since DR(-) AML and AML with NPM1 mutation share such characteristics as normal karyotype, the absence of CD34, and FLT3-ITD. NPM1 mutation was found in 18 of 26 (69.2%) of DR(-) cases, but not in any of 28 DR(+) cases. FLT3-ITD was noted in 66.7% of the cases with NPM1 mutation. These findings point to DR negativity as another phenotypic feature of AML with NPM1 mutation.

References

Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
Apr 29, 2006·The Journal of Molecular Diagnostics : JMD·Giovanni RotiUNKNOWN Gruppo Italiano Malattie Ematologiche dell' Adulto Working Party
Jun 24, 2006·Nature Reviews. Cancer·Silvia GrisendiPier Paolo Pandolfi
Oct 24, 2006·Leukemia Research·Meilani SyampurnawatiYoshitake Hayashi

❮ Previous
Next ❯

Citations

Oct 29, 2010·Journal of Hematology & Oncology·Maria BraoudakiFotini Tzortzatou-Stathopoulou
Oct 30, 2015·Laboratory Medicine·Erica Robinson, Carleen Van Siclen
Jan 21, 2015·Bioinformatics·Kieran O'NeillRyan R Brinkman
Jun 13, 2017·The Journal of Clinical Investigation·Catherine Matte-MartoneWarren D Shlomchik
Apr 4, 2021·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Andrea ZangrandoBarbara Buldini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.